Indication

BRAF V600E Unresectable or Metastatic Melanoma

1 clinical trial

1 product

Clinical trial

Multicenter, Open-label, Phase 1 Study Investigating the Safety and Tolerability of Encorafenib Monotherapy in BRAF V600E-mutated Chinese Patients With Advanced Metastatic Solid Tumors

Status: Completed, Estimated PCD: 2022-05-06

Product